Results 71 to 80 of about 17,592 (206)

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

BMC Cancer
Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i).
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group   +11 more
doaj   +1 more source

Profile of palbociclib in the treatment of metastatic breast cancer

, 2016
Moataz Ehab,1 Mohamad Elbaz2,31Department of Pharmacy Practice, 2Department of Pharmacology, Pharmacy School, Helwan University, Egypt; 3Department of Pathology, The Comprehensive Cancer Center, The Ohio State University Wexner Medical Center ...
Ehab M, Elbaz M
core  

Genetic variant within CDK6 regulates immune response to palbociclib treatment

, 2022
Everyone carries a set of genetic variants that contribute to regulation of the levels of blood cells, with unknown clinical impact. One of them, rs445 within the cell-cycle checkpoint gene CDK6, reduces the levels of myeloid cell types including ...
Orru V., Steri M., Zoledziewska M., Fiorillo E., Serra V., Cucca F.   +5 more
core   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

Advances in Radiation Oncology, 2019
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the ...
Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD   +8 more
doaj   +1 more source

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

, 2014
Karen A Cadoo, Ayca Gucalp, Tiffany A TrainaBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USAAbstract: Cellular proliferation, growth, and division following DNA ...
Gucalp A, Traina TA, Cadoo KA
core  

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models [PDF]

, 2019
Adequate drug distribution through tumours is essential for treatment to be effective. Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved for use in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer ...
Brook, BS, Holden, E.C., Hubbard, Matthew E, Spencer, Jade A, Smye, Stephen W, Loadman, P, Twelves, Christopher J, Spencer, JA, Spencer, Jade A., Loadman, Paul, O'Dea, RD, Hubbard, M.E., Smye, S.W., Brook, B.S., O'Dea, Reuben D, O'Dea, R.D., Jove, M, Holden, Elizabeth C, Jove, Maria, Jove, M., Holden, EC, Brook, Bindi S, Phillips, Roger M., Hubbard, ME, Twelves, C.J., Phillips, RM, Phillips, Roger M, Smye, SW, Twelves, CJ   +28 more
core   +1 more source

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, Volume 48, Issue 7, Page E70-E75, July 2026.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Eficacia relativa de Palbociclib y Ribociclib en el tratamiento de cáncer de mama localmente avanzado o metastásico: comparación Indirecta

, 2018
Se evalúa la eficacia relativa de palbociclib-letrozol y ribociclib-letrozol en mujeres postmenopáusicas con cáncer de mama avanzado ER positivo HER2 negativo que no habían recibido terapia sistémica previa para la enfermedad avanzada a través de ...
Valle Corpas, Margarita, Ubago Pérez, Ruth, Acosta García, Héctor   +2 more
core